Forecast

There is no analyst data available for this company.

News Go to news feed

BICO increases margins sharply in Q2 2026 – shares jump about 13%

BICO reported Q2 2026 revenue of SEK 336m (organic +7%) and a strong improvement in profitability: adjusted EBITDA margin 6% (vs. −2.6% year earlier) and gross margin 59% (vs. 44%). The company cites product mix and more direct sales as drivers, introduced new products and turned net debt into net cash of SEK 207m. Operating cash flow remained negative; net working capital fell to 10% of revenue for the last 12 months. The stock rose in pre-market trading by about 13% to $18.86, with investors viewing the margin and balance-sheet improvements positively. » More on de.investing.com
BICO increases organic growth thanks to lab automation, margins return

BICO reports Q3 2025 net sales of SEK 387m (+5% reported, +12% organic) and adjusted EBITDA of SEK 17m (margin 5%). The main driver was the Lab Automation segment with 35% organic growth and large orders from Biosero; Life Science Solutions grew moderately. Through the sale of MatTek and Visikol, BICO increased cash reserves to SEK 1,241m, despite non-cash impairments on Discover ECHO and Biosero. Management confirms a long-term growth guidance of around 10% CAGR and emphasizes a focus on lab automation and operational efficiency. » More on de.investing.com
BICO Group Q2 2025 disappoints with revenue decline and sharp share plunge

BICO Group reported Q2 2025 revenue of USD 324 million (forecast USD 430.73 million), organic growth of -17% and adjusted EBITDA of -49 million USD, after which the stock fell about 22%. The company is selling non-core assets, increasing its cash reserve to USD 1.4 billion and shifting its focus from academic customers to pharma and biotech markets. Management emphasizes a strategic realignment and measures to improve operational efficiency but sees risks from macroeconomic uncertainty and a weak academic market. » More on de.investing.com

Financials

In the last quarter, BICO Group AB had revenue of 30,33M€ and net profit of −3,36M€

(EUR)	Jun 2026	YoY
Revenue	+30,33M	4,24%
Gross profit	+14,20M	11,14%
Net profit	−3,36M	79,69%
EBITDA	−2,97M	21,05%

Fundamentals

Metric	Value
Market capitalization	+123,43M€
Number of shares	69,07M
52-week high/low	+2,29€ - +1,17€
Dividends	No
Beta	2,54
P/E ratio	−1,67
PEG ratio	+0,02
P/B ratio	+0,89
P/S ratio	+0,91

Company profile

BICO Group AB (publ) ist als Bio-Konvergenzunternehmen in Nordamerika, Europa, Asien und international tätig. Das Unternehmen ist in zwei Segmenten tätig: Laboratory Solutions und Bioautomation. Das Segment Laboratory Solutions bietet 3D-Biodrucker, Hybridmikroskope, Einzelzell-Dosiergeräte und Liquid-Handling-Instrumente sowie Dienstleistungen und zugehörige Verbrauchsmaterialien wie Biotinten, Reagenzien, Mikroskoplinsen, Software, Druckköpfe und 3D-rekonstruiertes menschliches Gewebe für Anwendungen in regulatorischen Tests. Dieses Segment bietet auch Dienstleistungen in den Bereichen 3D-Zellkultur, 3D-Gewebebildgebung, Multiplex-Bildgebung und digitale Pathologie für Pharma- und Biotechnologieunternehmen an. Das Segment Bioautomation bietet Produkte in den Bereichen Präzisionsdosierung und Biosensorik für industrielle Kunden sowie Diagnoseautomatisierung und fortschrittliche Robotiklösungen für die medizinische und diagnostische Industrie. Darüber hinaus bietet es Lösungen für das industrielle Kernökosystem, Tissue Engineering, Multi-omics, Zelllinienentwicklung und Diagnostik. Das Unternehmen bedient in erster Linie die Medizin-, Pharma- und Kosmetikindustrie. Das Unternehmen war früher unter dem Namen Cellink AB (publ) bekannt und änderte im August 2021 seinen Namen in BICO Group AB (publ). BICO Group AB (publ) wurde im Jahr 2016 gegründet und hat seinen Sitz in Göteborg, Schweden.

Name	BICO Group AB
CEO	Maria Forss
Headquarters	Gothenburg, vg Sweden
Website	bico.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	11/03/2016
Employees	557